• Je něco špatně v tomto záznamu ?

Xenobiotic metabolizing enzymes and metabolism of anthelminthics in helminths

V. Cvilink, J. Lamka, L. Skálová

. 2009 ; 41 (1) : 8-26.

Jazyk angličtina Země Velká Británie

Typ dokumentu přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11016892
E-zdroje

NLK Medline Complete (EBSCOhost) od 1999-02-01 do Před 1 rokem

Anthelminthics remain the only accessible means in the struggle against helminth parasites, which cause significant morbidity and mortality in man and farm animals. The treatment of helminthic infections has become problematic because of frequent drug resistance of helminth parasites. The development of drug resistance can be facilitated by the action of xenobiotic metabolizing enzymes (XMEs). In all organisms, XMEs serve as an efficient defense against the potential negative action of xenobiotics. The activities of XMEs determine both desired and undesired effects of drugs, and the knowledge of drug metabolism is necessary for safe, effective pharmacotherapy. While human and mammalian XMEs have been intensively studied for many years, XMEs of helminth parasites have undergone relatively little investigation, so far. However, many types of XMEs, including oxidases, reductases, hydrolases, transferases, and transporters, have been described in several helminth species. XMEs of helminth parasites may protect these organisms from the toxic effects of anthelminthics. In case of certain anthelminthics, metabolic deactivation was reported in helminth larvae and/or adults. Moreover, if a helminth is in the repeated contact with an anthelminthic, it defends itself against the chemical stress by the induction of biotransformation enzymes or transporters. This induction can represent an advantageous defense strategy of the parasites and may facilitate the drug-resistance development.

000      
03089naa 2200433 a 4500
001      
bmc11016892
003      
CZ-PrNML
005      
20121122114901.0
008      
110628s2009 xxk e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Cvilink, Viktor. $7 _AN058741
245    10
$a Xenobiotic metabolizing enzymes and metabolism of anthelminthics in helminths / $c V. Cvilink, J. Lamka, L. Skálová
314    __
$a Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic.
520    9_
$a Anthelminthics remain the only accessible means in the struggle against helminth parasites, which cause significant morbidity and mortality in man and farm animals. The treatment of helminthic infections has become problematic because of frequent drug resistance of helminth parasites. The development of drug resistance can be facilitated by the action of xenobiotic metabolizing enzymes (XMEs). In all organisms, XMEs serve as an efficient defense against the potential negative action of xenobiotics. The activities of XMEs determine both desired and undesired effects of drugs, and the knowledge of drug metabolism is necessary for safe, effective pharmacotherapy. While human and mammalian XMEs have been intensively studied for many years, XMEs of helminth parasites have undergone relatively little investigation, so far. However, many types of XMEs, including oxidases, reductases, hydrolases, transferases, and transporters, have been described in several helminth species. XMEs of helminth parasites may protect these organisms from the toxic effects of anthelminthics. In case of certain anthelminthics, metabolic deactivation was reported in helminth larvae and/or adults. Moreover, if a helminth is in the repeated contact with an anthelminthic, it defends itself against the chemical stress by the induction of biotransformation enzymes or transporters. This induction can represent an advantageous defense strategy of the parasites and may facilitate the drug-resistance development.
590    __
$a bohemika - dle Pubmed
650    _2
$a zvířata $7 D000818
650    _2
$a anthelmintika $x farmakologie $x metabolismus $7 D000871
650    _2
$a biologický transport $7 D001692
650    _2
$a biotransformace $7 D001711
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    _2
$a léková rezistence $7 D004351
650    _2
$a glutathiontransferasa $x metabolismus $7 D005982
650    _2
$a cizopasní červi $x enzymologie $x metabolismus $x účinky léků $7 D006376
650    _2
$a lidé $7 D006801
650    _2
$a I. fáze biotransformace $7 D050216
650    _2
$a II. fáze biotransformace $7 D050217
650    _2
$a druhová specificita $7 D013045
650    _2
$a xenobiotika $x farmakologie $x metabolismus $7 D015262
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lamka, Jiří, $d 1953- $7 nlk19990073481
700    1_
$a Skálová, Lenka, $d 1965- $7 mzk2004230464
773    0_
$t Drug Metabolism Reviews $w MED00001447 $g Roč. 41, č. 1 (2009), s. 8-26
910    __
$a ABA008 $b x $y 2
990    __
$a 20110720093131 $b ABA008
991    __
$a 20121122114924 $b ABA008
999    __
$a ok $b bmc $g 864116 $s 726684
BAS    __
$a 3
BMC    __
$a 2009 $x MED00001447 $b 41 $c 1 $d 8-26 $m Drug metabolism reviews $n Drug Metab Rev
LZP    __
$a 2011-3B09/BBjvme

Najít záznam